Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

BACKGROUND: Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance. PATIENTS AND METHODS: Prospective, multicente...

Full description

Saved in:
Bibliographic Details
Main Authors: Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2014
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143095/
https://ncbi.nlm.nih.gov/pubmed/25122671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu237
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items